Current Approaches in Treatment of Triple-negative Breast Cancer

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2015 Jul 16

PMID 26175926

Citations 277

Authors

Hanan Ahmed Wahba

Hend Ahmed El-Hadaad

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women and is highly prevalent in African American women. TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2. So patients with TNBC do not benefit from hormonal or trastuzumab-based therapies. TNBCs are biologically aggressive, although some reports suggest that they respond to chemotherapy better than other types of breast cancer, prognosis remains poor. This is due to: shortened disease-free interval in the adjuvant and neoadjuvant setting and a more aggressive course in the metastatic setting.

Citing Articles

Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.

Handa S, Puri S, Chatterjee M, Puri V Bioinform Biol Insights. 2025; 19:11779322241271565.

PMID: 40034579 PMC: 11873876. DOI: 10.1177/11779322241271565.

Engineered zwitterionic diblock copolymer-siRNA polyplexes provide highly effective treatment of triple-negative breast cancer in a 4T1 murine model.

Jeon T, Goswami R, Nagaraj H, Cicek Y, Lehot V, Welton J Adv Funct Mater. 2025; 34(42).

PMID: 40017807 PMC: 11864752. DOI: 10.1002/adfm.202406763.

Pristimerin Promotes Ubiquitination of HSPA8 and Activates the VAV1/ERK Pathway to Suppress TNBC Proliferation.

Liu Q, Fan Q, Chen J, Liu J, Li Y, Luo Q Adv Sci (Weinh). 2025; 12(10):e2413174.

PMID: 39813169 PMC: 11904939. DOI: 10.1002/advs.202413174.

Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models.

Lyu S, Meshesha S, Hong C Int J Mol Sci. 2025; 26(1.

PMID: 39796221 PMC: 11719730. DOI: 10.3390/ijms26010366.

Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer.

Nemours S, Sole C, Goicoechea I, Armesto M, Arestin M, Urruticoechea A Int J Mol Sci. 2025; 25(24.

PMID: 39769392 PMC: 11728027. DOI: 10.3390/ijms252413630.

References

Panoff J, Hurley J, Takita C, Reis I, Zhao W, Sujoy V . Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 2011; 128(3):899-906. DOI: 10.1007/s10549-011-1495-1. View

Ibrahim N, Desai N, Legha S, Soon-Shiong P, Theriault R, Rivera E . Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002; 8(5):1038-44. View

Ismail-Khan R, Bui M . A review of triple-negative breast cancer. Cancer Control. 2010; 17(3):173-6. DOI: 10.1177/107327481001700305. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, OReilly T . The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120(6):747-59. DOI: 10.1016/j.cell.2004.12.040. View

Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, DAiuto M . Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 2009; 20(7):1185-92. DOI: 10.1093/annonc/mdn748. View

Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794-803. DOI: 10.1200/JCO.2005.04.937. View

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

10.

Cleator S, Heller W, Coombes R . Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8(3):235-44. DOI: 10.1016/S1470-2045(07)70074-8. View

11.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

12.

Verma S, Provencher L, Dent R . Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol. 2011; 18(4):180-90. PMC: 3149546. DOI: 10.3747/co.v18i4.913. View

13.

Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Soto M . Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov. 2008; 1(1):39-53. DOI: 10.2174/157489206775246430. View

14.

Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H . Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013; 24(12):2978-84. DOI: 10.1093/annonc/mdt361. View

15.

Harris L, Broadwater G, Lin N, Miron A, Schnitt S, Cowan D . Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66. PMC: 1797029. DOI: 10.1186/bcr1622. View

16.

Harding J, Burtness B . Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005; 41(2):107-27. DOI: 10.1358/dot.2005.41.2.882662. View

17.

Lin N, Claus E, Sohl J, Razzak A, Arnaout A, Winer E . Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113(10):2638-45. PMC: 2835546. DOI: 10.1002/cncr.23930. View

18.

Rakha E, Reis-Filho J, Ellis I . Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26(15):2568-81. DOI: 10.1200/JCO.2007.13.1748. View

19.

Gennari A, Sormani M, Pronzato P, Puntoni M, Colozza M, Pfeffer U . HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2007; 100(1):14-20. DOI: 10.1093/jnci/djm252. View

20.

Geisler S, Lonning P, Aas T, Johnsen H, Fluge O, Haugen D . Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001; 61(6):2505-12. View